Innate Pharma SA (IPHA)
About Innate Pharma SA
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $160.6M
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $160.6M
- Shares outstanding
- 90.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 9, 2015
Innate Pharma SA (IPHA) Stock Price
- Trading 25% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Innate Pharma SA.
Write a review
News about Innate Pharma SA
News & sentiment via Polygon.io
Innate Pharma SA: frequently asked questions
Is Innate Pharma SA an American company?
Innate Pharma SA is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Innate Pharma SA publicly traded?
Yes — Innate Pharma SA is a publicly traded company. Its stock trades under the ticker symbol IPHA on the NASDAQ.
What does Innate Pharma SA do?
Innate Pharma SA is an American Pharmaceuticals company in the Health & Beauty sector.
